AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
FDA Opens the Door to De-Identified Real-World Evidence in Regulatory Filings
The FDA has issued guidance that makes de-identified real-world evidence more usable in regulatory submissions, potentially broadening the data sources companies can bring to market. For drug and device developers, this could reduce reliance on traditional trials in some contexts while increasing pressure to prove data quality and provenance.
OpenAI Study Puts Diagnostic AI Marketing Under the Microscope
eMarketer’s coverage of an OpenAI-versus-doctors study suggests the latest debate is not just about AI performance, but about how vendors frame that performance. Diagnostic AI marketing is increasingly being judged against the hard realities of clinical validity. That scrutiny could reshape how companies talk about their products, especially when the evidence comes from narrow tests rather than durable clinical outcomes.
Rare disease AI promises progress, but the evidence gap is still the bottleneck
Open Access Government asks whether AI can live up to its promises for rare diseases, where data scarcity and fragmented care have long constrained diagnosis and treatment. The central challenge is not model ambition, but proof in low-volume, high-variability conditions.
Philips pushes for proof, scale, and sharing as healthcare AI enters its commercialization phase
Philips is emphasizing evidence generation and replication as the healthcare AI market matures. The message is that vendors will increasingly be judged on demonstrated outcomes, not just technical novelty.
Top medical journal publishes harsh warning against medical AI
Futurism reports that a top medical journal published a searing critique of medical AI, adding a cautionary counterpoint to the recent wave of upbeat performance studies. The warning reflects a growing concern that enthusiasm is outrunning evidence in some corners of healthcare technology.
The Real AI Healthcare Debate Is No Longer Hype — It’s Proof
Digital Health Wire’s roundup captures a growing skepticism around healthcare AI, including the gap between expectations and reality and the problem of vendor sprawl. The conversation is shifting from whether AI can work to whether it can prove value inside messy, real-world systems.
Healthcare’s AI Race Is Moving From Scribes to Systems
Abridge’s partnership with medical journals shows how AI clinical decision support is trying to move beyond note-taking into evidence-linked workflow tools. The shift suggests the next battle in healthcare AI will be over how knowledge is surfaced, trusted, and integrated into care.
FDA Warns Researchers and Companies to Stop Suppressing Unfavorable Trial Results
The FDA has warned thousands of companies and researchers against hiding negative clinical trial outcomes, underscoring concerns about transparency in medical evidence generation. The move puts renewed pressure on sponsors to treat unfavorable data as part of the scientific record, not a PR problem.
FDA Warns Against Suppressing Negative Trial Results as Transparency Enforcement Intensifies
The FDA has warned thousands of companies and researchers against suppressing unfavorable clinical trial results, signaling a tougher stance on transparency. The message is especially relevant as more healthcare innovation depends on data credibility.
FDA Reminds Sponsors and Researchers to Disclose Clinical Trial Results
The FDA is reminding sponsors and researchers about the requirement to disclose clinical trial results, putting transparency back in focus for the drug and device ecosystem. The move underscores that public accountability remains a core part of biomedical research, even as attention shifts toward faster development and AI-enabled discovery.
FDA patient preference guidance signals a broader evidence model for medical devices
New CDRH guidance on patient preference information highlights the FDA’s continued push to incorporate patient values into device decision-making. The policy is notable because it widens the definition of meaningful evidence beyond technical performance and traditional clinical endpoints.
MIT Technology Review Spotlights the Hard Question in Healthcare AI: Does It Actually Work?
A new MIT Technology Review piece argues that the explosion of AI health tools is outpacing the evidence needed to judge their real-world value. The story matters because it reframes healthcare AI from a product-launch narrative into an outcomes, validation, and implementation problem.
ASCO asks the oncology field’s hard AI question: are we actually ready for routine care?
A new ASCO Post overview captures oncology’s central AI tension: the technology is already useful in pockets of care, but broad clinical deployment still faces evidence, workflow, and trust gaps. The piece is significant because it frames cancer AI not as a future promise, but as a present implementation problem.
Pediatric AI Is Advancing Faster Than the Evidence Base
A new AJMC report highlights the promise of large language models in pediatric care while underscoring a central constraint: safety and efficacy data remain too thin for broad clinical reliance. The pediatric setting raises a higher bar because developmental nuance, family communication, and lower tolerance for error make general-purpose AI weaknesses more consequential.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.